Alexandre Chlenski
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Alexandre Chlenski has a total of 34 co-authors. Here are the top co-authors by number of shared publications:
- Mark A. Applebaum
Department of Pediatrics University of Chicago Chicago Illinois USA
35 shared publications - Susan Lerner Cohn
Department of Pediatrics University of Chicago Chicago Illinois USA
34 shared publications - Chuan He
Department of Chemistry, University of Chicago, Chicago, USA
33 shared publications - Omar R. Vayani
Department of Pediatrics University of Chicago Chicago Illinois USA
33 shared publications - Kelley Moore
Division of Hematology/Oncology, Department of Pediatrics University of Chicago Pritzker School of Medicine Chicago Illinois USA
32 shared publications - Ami Vijay Desai
Division of Pediatric Hematology & Oncology, University of Chicago, Chicago, IL
31 shared publications
Latest Publications
- Open Access
- 12 July 2026
- Published by Wiley in Clinical and Translational Science
- Vol. 19 (7) , e70665
Reply to: “Hypoxia‐Induced Lineage Plasticity in Neuroblastoma: Advancing Signature Interpretation and Clinical Translation”
- 12 July 2026
- Published by Wiley in Clinical and Translational Science
- Vol. 19 (7) , e70665
Open AccessReply to: “Hypoxia‐Induced Lineage Plasticity in Neuroblastoma: Advancing Signature Interpretation and Clinical Translation”
- Open Access
- 10 June 2026
- Published by Wiley in Clinical and Translational Science
- Vol. 19 (6) , e70627
A Bayesian‐Based Integrative Bioinformatics Analysis Nominates Oncogenic Drivers in Neuroblastoma
Identifying targetable oncogenic drivers remains a challenge in neuroblastoma, the most common extracranial solid malignancy in children. We applied a Bayesian algorithm for integrative analysis of expression and copy‐number, iExCN, to nominate oncogenic drivers in neuroblastoma. The iExCN algorithm found 47 oncogenes from a dataset of 195 neuroblastoma biopsy specimens. The nominated oncogenes included some previously implicated in neuroblastoma, including ALK , MDM2 , MYCN , and XPO1 , but most have not been linked to this disease. A CRISPR/Cas9‐based screen testing those candidates revealed neuroblastoma cell line‐specific and shared vulnerabilities in three well‐characterized models, and dependencies were confirmed by complementary RNA knockdown. Analysis of more than 30 additional neuroblastoma cell lines using DepMap confirmed statistically significant dependency scores in the iExCN genes. Finally, analysis of two cohorts of children with neuroblastoma revealed a trend toward worse survival in cases in which more iExCN genes showed copy number gains. Our findings uncover multiple, potentially targetable oncogenic drivers that appear to influence neuroblastoma biology, demonstrating a generalizable capacity for iExCN to unmask disease genes and therapeutic targets in cancer.
- 10 June 2026
- Published by Wiley in Clinical and Translational Science
- Vol. 19 (6) , e70627
Open AccessA Bayesian‐Based Integrative Bioinformatics Analysis Nominates Oncogenic Drivers in Neuroblastoma
Identifying targetable oncogenic drivers remains a challenge in neuroblastoma, the most common extracranial solid malignancy in children. We applied a Bayesian algorithm for integrative analysis of expression and copy‐number, iExCN, to nominate oncogenic drivers in neuroblastoma. The iExCN algorithm found 47 oncogenes from a dataset of 195 neuroblastoma biopsy specimens. The nominated oncogenes included some previously implicated in neuroblastoma, including ALK , MDM2 , MYCN , and XPO1 , but most have not been linked to this disease. A CRISPR/Cas9‐based screen testing those candidates revealed neuroblastoma cell line‐specific and shared vulnerabilities in three well‐characterized models, and dependencies were confirmed by complementary RNA knockdown. Analysis of more than 30 additional neuroblastoma cell lines using DepMap confirmed statistically significant dependency scores in the iExCN genes. Finally, analysis of two cohorts of children with neuroblastoma revealed a trend toward worse survival in cases in which more iExCN genes showed copy number gains. Our findings uncover multiple, potentially targetable oncogenic drivers that appear to influence neuroblastoma biology, demonstrating a generalizable capacity for iExCN to unmask disease genes and therapeutic targets in cancer.
- Open Access
- 22 February 2026
- Published by Wiley in Clinical and Translational Science
- Vol. 19 (3) , e70508
Hypoxia Promotes an Adrenergic to Mesenchymal Transcriptional Program Transition in Neuroblastoma
Adrenergic (ADRN) neuroblastoma cells have a paradoxical increase in TET1 expression and 5‐hydroxymethylcytosine (5‐hmC) deposition in hypoxia. However, the effect of hypoxia on the mesenchymal (MES) lineage remains less well understood. To identify lineage specific hypoxia responses, we evaluated 5‐hmC and RNA expression in a panel of ADRN and MES cells cultured in normoxic or hypoxic conditions. In hypoxia, MES cells had only a modestly elevated expression of hypoxia signaling and no phenotypic changes. In contrast, ADRN cells showed increased 5‐hmC deposition and decreased mitochondrial function in hypoxia. In hypoxia, only ADRN cells had increased expression of MES signature genes ( p < 0.05) and related pathways including TNF‐α signaling. Publicly available RNA‐Seq data of diagnostic tumors was accessed (GSE62564 and GSE73517). Each tumor was assigned a hypoxia score using a published hypoxia signature. A MES/hypoxia signature comprising 94 MES signature genes that had increased expression in ADRN cells exposed to hypoxia was also generated. This MES/hypoxia signature was significantly correlated with a T cell infiltration signature ( r = 0.66, p = 2.3 × 10 −12 ). Kaplan–Meier analysis and the log rank test assessed overall survival (OS) differences between groups. High‐risk patients with hypoxic tumors that had high MES/hypoxia scores had significantly improved 3‐year OS compared to those with low MES/hypoxia scores (71% vs. 40%; p = 0.0054). Superior survival was also observed in high‐risk patients with hypoxic tumors that had high MES/hypoxia scores in the validation cohort (GSE73517; n = 28; 3‐year OS 78% vs. 26%, p = 0.0012). Our results suggest that hypoxia changes expression of genes in ADRN cells towards MES cells.
- 22 February 2026
- Published by Wiley in Clinical and Translational Science
- Vol. 19 (3) , e70508
Open AccessHypoxia Promotes an Adrenergic to Mesenchymal Transcriptional Program Transition in Neuroblastoma
Adrenergic (ADRN) neuroblastoma cells have a paradoxical increase in TET1 expression and 5‐hydroxymethylcytosine (5‐hmC) deposition in hypoxia. However, the effect of hypoxia on the mesenchymal (MES) lineage remains less well understood. To identify lineage specific hypoxia responses, we evaluated 5‐hmC and RNA expression in a panel of ADRN and MES cells cultured in normoxic or hypoxic conditions. In hypoxia, MES cells had only a modestly elevated expression of hypoxia signaling and no phenotypic changes. In contrast, ADRN cells showed increased 5‐hmC deposition and decreased mitochondrial function in hypoxia. In hypoxia, only ADRN cells had increased expression of MES signature genes ( p < 0.05) and related pathways including TNF‐α signaling. Publicly available RNA‐Seq data of diagnostic tumors was accessed (GSE62564 and GSE73517). Each tumor was assigned a hypoxia score using a published hypoxia signature. A MES/hypoxia signature comprising 94 MES signature genes that had increased expression in ADRN cells exposed to hypoxia was also generated. This MES/hypoxia signature was significantly correlated with a T cell infiltration signature ( r = 0.66, p = 2.3 × 10 −12 ). Kaplan–Meier analysis and the log rank test assessed overall survival (OS) differences between groups. High‐risk patients with hypoxic tumors that had high MES/hypoxia scores had significantly improved 3‐year OS compared to those with low MES/hypoxia scores (71% vs. 40%; p = 0.0054). Superior survival was also observed in high‐risk patients with hypoxic tumors that had high MES/hypoxia scores in the validation cohort (GSE73517; n = 28; 3‐year OS 78% vs. 26%, p = 0.0012). Our results suggest that hypoxia changes expression of genes in ADRN cells towards MES cells.
- Open Access
- 26 March 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S1 from Characterizing Relationships between T-cell Inflammation and Outcomes in Patients with High-Risk Neuroblastoma According to Mesenchymal and Adrenergic Signatures
Hockey stick plots representing H3K27ac signal strength and enhancer rank to identify super-enhancers in each of the neuroblastoma cell lines.
- 26 March 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S1 from Characterizing Relationships between T-cell Inflammation and Outcomes in Patients with High-Risk Neuroblastoma According to Mesenchymal and Adrenergic Signatures
Hockey stick plots representing H3K27ac signal strength and enhancer rank to identify super-enhancers in each of the neuroblastoma cell lines.
- Open Access
- 26 March 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Table S2 from Characterizing Relationships between T-cell Inflammation and Outcomes in Patients with High-Risk Neuroblastoma According to Mesenchymal and Adrenergic Signatures
373 genes identified near single-stranded super-enhancers associated with adrenergic cell state.
- 26 March 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S2 from Characterizing Relationships between T-cell Inflammation and Outcomes in Patients with High-Risk Neuroblastoma According to Mesenchymal and Adrenergic Signatures
373 genes identified near single-stranded super-enhancers associated with adrenergic cell state.
- Open Access
- 26 March 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Table S3 from Characterizing Relationships between T-cell Inflammation and Outcomes in Patients with High-Risk Neuroblastoma According to Mesenchymal and Adrenergic Signatures
Table comparing our novel adrenergic and mesenchymal gene signatures with previously published signatures by Van Gronigen et al and Boeva et al.
- 26 March 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S3 from Characterizing Relationships between T-cell Inflammation and Outcomes in Patients with High-Risk Neuroblastoma According to Mesenchymal and Adrenergic Signatures
Table comparing our novel adrenergic and mesenchymal gene signatures with previously published signatures by Van Gronigen et al and Boeva et al.
- Open Access
- 26 March 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Table S1 from Characterizing Relationships between T-cell Inflammation and Outcomes in Patients with High-Risk Neuroblastoma According to Mesenchymal and Adrenergic Signatures
159 genes identified near single-stranded super-enhancers associated with mesenchymal cell state.
- 26 March 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S1 from Characterizing Relationships between T-cell Inflammation and Outcomes in Patients with High-Risk Neuroblastoma According to Mesenchymal and Adrenergic Signatures
159 genes identified near single-stranded super-enhancers associated with mesenchymal cell state.
- Open Access
- 26 March 2025
- Published by American Association for Cancer Research (AACR)
Figure 1 from Characterizing Relationships between T-cell Inflammation and Outcomes in Patients with High-Risk Neuroblastoma According to Mesenchymal and Adrenergic Signatures
SsSEs identify highly expressed genes unique to the ADRN and MES lineages. A, H3K27ac deposition on ADRN and MES SEs and ssSE in each neuroblastoma cell line. Peaks are higher for ssSEs than double-stranded SEs. B, H3K27ac deposition, KAS-seq pulldown, and RNA expression at MES ssSE, denoted in red, associated with a MES signature gene LUM in representative ADRN and MES isogenic cell lines and C, a ADRN signature gene PRIMA1 in the same representative cell lines. D, Heatmap representing 532 differentially expressed genes that were identified in five ADRN and three MES cell lines in proximity to ssSEs (P < 0.05).
- 26 March 2025
- Published by American Association for Cancer Research (AACR)
Open AccessFigure 1 from Characterizing Relationships between T-cell Inflammation and Outcomes in Patients with High-Risk Neuroblastoma According to Mesenchymal and Adrenergic Signatures
SsSEs identify highly expressed genes unique to the ADRN and MES lineages. A, H3K27ac deposition on ADRN and MES SEs and ssSE in each neuroblastoma cell line. Peaks are higher for ssSEs than double-stranded SEs. B, H3K27ac deposition, KAS-seq pulldown, and RNA expression at MES ssSE, denoted in red, associated with a MES signature gene LUM in representative ADRN and MES isogenic cell lines and C, a ADRN signature gene PRIMA1 in the same representative cell lines. D, Heatmap representing 532 differentially expressed genes that were identified in five ADRN and three MES cell lines in proximity to ssSEs (P < 0.05).
- Open Access
- 26 March 2025
- Published by American Association for Cancer Research (AACR)
Figure 4 from Characterizing Relationships between T-cell Inflammation and Outcomes in Patients with High-Risk Neuroblastoma According to Mesenchymal and Adrenergic Signatures
MESadj and TCI scores are inversely correlated with features of high-risk neuroblastoma. MESadj and TCI are correlated in both the (A) Discovery and (B) Validation cohorts and inversely correlated with MYCN amplification, stage, and age in the Discovery cohort. Colored circle representing the correlation coefficient shown only for those correlations with P < 0.05. In the Discovery cohort, TCI and MESadj decrease with increasing stage (C and D), although 4S tumors have lower TCI and higher MESadj.
- 26 March 2025
- Published by American Association for Cancer Research (AACR)
Open AccessFigure 4 from Characterizing Relationships between T-cell Inflammation and Outcomes in Patients with High-Risk Neuroblastoma According to Mesenchymal and Adrenergic Signatures
MESadj and TCI scores are inversely correlated with features of high-risk neuroblastoma. MESadj and TCI are correlated in both the (A) Discovery and (B) Validation cohorts and inversely correlated with MYCN amplification, stage, and age in the Discovery cohort. Colored circle representing the correlation coefficient shown only for those correlations with P < 0.05. In the Discovery cohort, TCI and MESadj decrease with increasing stage (C and D), although 4S tumors have lower TCI and higher MESadj.
- Open Access
- 26 March 2025
- Published by American Association for Cancer Research (AACR)
Data from Characterizing Relationships between T-cell Inflammation and Outcomes in Patients with High-Risk Neuroblastoma According to Mesenchymal and Adrenergic Signatures
Recent insights have identified adrenergic (ADRN) and mesenchymal (MES) cell lineages as distinct biologic cell types and T-cell inflammation as a prognostic marker in neuroblastoma. We hypothesized that elucidating unique and overlapping aspects of these biologic features could serve as novel biomarkers for informing ongoing efforts to improve therapeutic approaches for children with high-risk neuroblastoma. We identified lineage-specific, single-stranded super-enhancers to define ADRN and MES specific genes. Publicly available RNA-seq of diagnostic tumor biopsies was used in Discovery and Validation cohorts. Each tumor was assigned a relative MES score and T-cell inflammation (TCI) score. Survival was assessed using the Kaplan–Meier method, and differences were assessed by the log-rank test. Inflammation scores were correlated with MES scores and anticorrelated with MYCN-amplification in both cohorts. Among patients with high-risk, ADRN tumors, those with TCI tumors had superior overall survival to those with non-inflamed tumors. A similar, but nonsignificant, trend was observed in the Validation cohort. Conversely, there was no difference according to TCI status in the MES cohort in either the Discover or Validation cohorts. High-inflammation scores were correlated with improved survival in some patients with high-risk, ADRN but not MES neuroblastoma. Our findings bolster support for further developing T-cell-based and immunotherapy-based approaches for children with high-risk neuroblastoma of varying MES and ADRN expression.Significance:Adrenergic (ADRN) and mesenchymal (MES) lineages are distinct biologic cell types in neuroblastoma. We defined ADRN and MES specific genes and found that high-risk, ADRN tumors harboring elevated T-cell inflammation signatures had superior overall survival. Our findings bolster support for further developing immunotherapy-based approaches for children with high-risk neuroblastoma.
- 26 March 2025
- Published by American Association for Cancer Research (AACR)
Open AccessData from Characterizing Relationships between T-cell Inflammation and Outcomes in Patients with High-Risk Neuroblastoma According to Mesenchymal and Adrenergic Signatures
Recent insights have identified adrenergic (ADRN) and mesenchymal (MES) cell lineages as distinct biologic cell types and T-cell inflammation as a prognostic marker in neuroblastoma. We hypothesized that elucidating unique and overlapping aspects of these biologic features could serve as novel biomarkers for informing ongoing efforts to improve therapeutic approaches for children with high-risk neuroblastoma. We identified lineage-specific, single-stranded super-enhancers to define ADRN and MES specific genes. Publicly available RNA-seq of diagnostic tumor biopsies was used in Discovery and Validation cohorts. Each tumor was assigned a relative MES score and T-cell inflammation (TCI) score. Survival was assessed using the Kaplan–Meier method, and differences were assessed by the log-rank test. Inflammation scores were correlated with MES scores and anticorrelated with MYCN-amplification in both cohorts. Among patients with high-risk, ADRN tumors, those with TCI tumors had superior overall survival to those with non-inflamed tumors. A similar, but nonsignificant, trend was observed in the Validation cohort. Conversely, there was no difference according to TCI status in the MES cohort in either the Discover or Validation cohorts. High-inflammation scores were correlated with improved survival in some patients with high-risk, ADRN but not MES neuroblastoma. Our findings bolster support for further developing T-cell-based and immunotherapy-based approaches for children with high-risk neuroblastoma of varying MES and ADRN expression.Significance:Adrenergic (ADRN) and mesenchymal (MES) lineages are distinct biologic cell types in neuroblastoma. We defined ADRN and MES specific genes and found that high-risk, ADRN tumors harboring elevated T-cell inflammation signatures had superior overall survival. Our findings bolster support for further developing immunotherapy-based approaches for children with high-risk neuroblastoma.